Drug intelligence / Profile preview

YKST05

Development stage: Preclinical
Lead developer: Excyte Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YKST05 is a preclinical-stage bispecific antibody being developed by Excyte Biopharma. While specific molecular targets have not been definitively disclosed in public pipeline summaries, the drug is part of a broader portfolio of bispecific and trispecific antibodies focused on oncology. The program is currently in the early stages of development, following the company's lead programs YK012 and YKST02 which target CD19/CD3 and BCMA/CD3 respectively. Due to the early nature of the program, the exact mechanism of action and primary oncology indication remain to be fully characterized.

Beyond the preview

Go deeper on YKST05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YKST05.

Explore the full profile